Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ixabepilone

FDA-approved product (injectable, intravenous), marketed as Ixempra Kit.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ixabepilone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other cytotoxic antibiotics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ixabepilone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ixabepilone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer

    NCT00825734 · start 2009-03

    Registered record
    Registry ID
    NCT00825734
    Conditions
    Metastatic Breast Cancer
    Interventions
    Sorafenib; Ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2009-03
    Completion
    2014-08
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionSorafenib; Ixabepilone
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer

    NCT00765765 · start 2009-02

    Registered record
    Registry ID
    NCT00765765
    Conditions
    Breast Cancer
    Interventions
    hydroxychloroquine; ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2009-02
    Completion
    2011-12
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionhydroxychloroquine; ixabepilone
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer

    NCT00821886 · start 2009-02

    Registered record
    Registry ID
    NCT00821886
    Conditions
    Breast Cancer
    Interventions
    Ixabepilone; Trastuzumab; Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-02
    Completion
    2014-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionIxabepilone; Trastuzumab; Carboplatin
    PhasePhase 2
    Registry statusCompleted

  • Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer

    NCT00828308 · start 2009-02

    Registered record
    Registry ID
    NCT00828308
    Conditions
    Prostate Cancer
    Interventions
    Ixabepilone; Prostatectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-02
    Completion
    2016-12
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionIxabepilone; Prostatectomy
    PhasePhase 2
    Registry statusCompleted

  • A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

    NCT00723957 · start 2008-12

    Registered record
    Registry ID
    NCT00723957
    Conditions
    Advanced/Metastatic Non-Small Cell Lung Cancer
    Interventions
    Ixabepilone, 32 mg/m^2; Paclitaxel, 200 mg/m^2; Carboplatin (area under the concentration curve [AUC] 6)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-12
    Completion
    2011-08
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced/Metastatic Non-Small Cell Lung Cancer
    InterventionIxabepilone, 32 mg/m^2; Paclitaxel, 200 mg/m^2; Carboplatin (area under the concentration curve [AUC] 6)
    PhasePhase 2
    Registry statusCompleted

  • A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer

    NCT00789581 · start 2008-12

    Registered record
    Registry ID
    NCT00789581
    Conditions
    Breast Cancer
    Interventions
    Doxorubicin; Cyclophosphamide; Ixabepilone (Ixempra); Paclitaxel (Taxol)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-12
    Completion
    2016-11
    Enrolment
    614

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionDoxorubicin; Cyclophosphamide; Ixabepilone (Ixempra); Paclitaxel (Taxol)
    PhasePhase 3
    Registry statusCompleted

  • Ixabepilone to Treat Cervical Cancer

    NCT00924066 · start 2008-11

    Registered record
    Registry ID
    NCT00924066
    Conditions
    Cervical Carcinoma; Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Carcinoma, Non-SquamousType
    Interventions
    Ixempra (Ixabepilone (BMS-247550) )
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-11
    Completion
    2013-12
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCervical Carcinoma; Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Carcinoma, Non-SquamousType
    InterventionIxempra (Ixabepilone (BMS-247550) )
    PhasePhase 2
    Registry statusTerminated

  • Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

    NCT00785291 · start 2008-10-13

    Registered record
    Registry ID
    NCT00785291
    Conditions
    Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer AJCC v6 and v7
    Interventions
    Bevacizumab; Ixabepilone; Laboratory Biomarker Analysis; Nab-paclitaxel; Paclitaxel; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-10-13
    Completion
    2017-06-15
    Enrolment
    799

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive +5 more
    InterventionBevacizumab; Ixabepilone; Laboratory Biomarker Analysis; Nab-paclitaxel +2 more
    PhasePhase 3
    Registry statusCompleted

  • Neo-Adjuvant Study in Triple Negative Breast Cancer Patients

    NCT01097642 · start 2008-10-10

    Registered record
    Registry ID
    NCT01097642
    Conditions
    Breast Cancer
    Interventions
    Cetuximab; Ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10-10
    Completion
    2019-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionCetuximab; Ixabepilone
    PhasePhase 2
    Registry statusCompleted

  • Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer

    NCT00741988 · start 2008-09

    Registered record
    Registry ID
    NCT00741988
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Ixabepilone; Carboplatin; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-09
    Completion
    2012-09
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionIxabepilone; Carboplatin; Bevacizumab
    PhasePhase 2
    Registry statusCompleted

  • FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC

    NCT00751868 · start 2008-09

    Registered record
    Registry ID
    NCT00751868
    Conditions
    Breast Cancer
    Interventions
    Ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-09
    Completion
    2011-07
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionIxabepilone
    PhasePhase 2
    Registry statusCompleted

  • Solid Tumors Using Ixabepilone and Dasatinib

    NCT00717704 · start 2008-07

    Registered record
    Registry ID
    NCT00717704
    Conditions
    Solid Tumor
    Interventions
    ixabepilone; Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-07
    Completion
    2011-05
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor
    Interventionixabepilone; Dasatinib
    PhasePhase 1
    Registry statusCompleted

  • Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer

    NCT00637897 · start 2008-03

    Registered record
    Registry ID
    NCT00637897
    Conditions
    Breast Cancer
    Interventions
    docetaxel; ixabepilone; paclitaxel; paclitaxel albumin-stabilized nanoparticle formulation; paricalcitol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-03
    Completion
    2013-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventiondocetaxel; ixabepilone; paclitaxel; paclitaxel albumin-stabilized nanoparticle formulation +1 more
    PhasePhase 1
    Registry statusCompleted

  • Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

    NCT00455533 · start 2007-10

    Registered record
    Registry ID
    NCT00455533
    Conditions
    Breast Cancer
    Interventions
    Ixabepilone; Paclitaxel; Cyclophosphamide; Doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-10
    Completion
    2009-12
    Enrolment
    384

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionIxabepilone; Paclitaxel; Cyclophosphamide; Doxorubicin
    PhasePhase 2
    Registry statusCompleted

  • Phase I Combination w/ Epirubicin

    NCT00322374 · start 2006-08

    Registered record
    Registry ID
    NCT00322374
    Conditions
    Metastatic Breast Cancer
    Interventions
    Ixabepilone; Epirubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-08
    Completion
    2009-02
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionIxabepilone; Epirubicin
    PhasePhase 1
    Registry statusCompleted